- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02868541
Assessment of Pharyngeal Carriage of Microorganisms Responsible for Transmissible Acute Respiratory Infections in HAJJ Pilgrims. (EMIRATH)
Assessment of Pharyngeal Carriage of Microorganisms Responsible for Transmissible Acute Respiratory Infections in HAJJ Pilgrims
The objective of this project is to study the prevalence of viruses and bacteria responsible for transmissible acute respiratory infections in the respiratory tract of pilgrims returning from the trip. The patients included, will be the consultant pilgrims to the traveler health center, and before leaving for Hajj. Based on the results obtained in previous studies, it is estimated that 200 pilgrims will be included each year, 600 in total (inclusion period of 3 years). Respiratory secretions are then collected by nasal swab and throat (swab) prior to departure for the hajj. In return, patients will be reconvened systematic consultation to record medical events potentially encountered during the trip, and it will again be performed the same nasal swabs and throat. It will then be performed on these samples' return from hajj "molecular detection (PCR and RT-PCR) of 35 viruses and bacteria respiratory tropism: influenza (3), RSV (2), metapneumovirus (1), Coronavirus (4), Parainfluenzavirus (4), enteroviruses (4), rhinovirus (1), adenovirus (6) bocavirus, polyomavirus (2), pneumococcus, Bordetella pertussis, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Coxiella burnetii. Samples "return of hajj" positive should be cultured for the isolation of the strain. For patients positive return, it will be done further research of these 35 viruses and bacteria on samples "start of hajj," the same method described above. In addition to this systematic consultation, and if symptoms return, the pilgrims will be seen in consultation for a diagnosis evaluation and therapeutic management.
This study will shed light on the acquisition of microorganisms respiratory tropism during the stay and on the potential risks associated with the circulation of these pathogens after the trip.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Marseille, France, 13354
- Assistance Publique Hopitaux de Marseille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All travelers presenting during the study period in the service of international vaccination for mandatory meningococcal ACYW135 vaccination ,
- Affiliated to a social security insurance regime
- Male or Female
- Aged over 18 years
- Having signed informed consent form
- able to understand and answer the study questions
Exclusion Criteria
- Patients aged under 18
- Patient whose protocol compliance seems unlikely to investigator
- Participant in another clinical trial or in exclusion period of a previous clinical trial,
- Unable to understand the nature and objectives of the study,
- Refusing to sign the informed consent form.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Haaj pilgrim
Patient that are showing at the traveler hospital health center requiring the mandatory Meningococcal vaccine ACYW135
|
Naso pharyngeal swab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of new viruses and/or bacteria identified and characterized by respiratory and pharyngeal carriage among pilgrims between the departure and the return of Hajj
Time Frame: up to 3 years
|
up to 3 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-29
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Infection
-
European Clinical Research Alliance for Infectious...UMC Utrecht; University of OxfordNot yet recruitingAcute Respiratory Infection | Acute Respiratory Tract Infection
-
Fundación Santa Fe de BogotaFedesarrollo; Pontificia Universidad Javeriana; Global Development NetworkCompletedAcute Respiratory Infection | Acute Diarrheal DiseaseColombia
-
Hanmi Pharmaceutical Company LimitedUnknownAcute Upper Respiratory Infection | Acute BronchitisKorea, Republic of
-
University of FloridaNational Institutes of Health (NIH); Universite d'Etat d'HaitiCompletedAcute Respiratory Infection | Acute Febrile Illness | Acute DiarrheaHaiti
-
NPO PetrovaxCompletedAcute Respiratory InfectionRussian Federation
-
Reckitt Benckiser LLCCompletedAcute Respiratory InfectionUnited States
-
University of Wisconsin, MadisonNational Center for Complementary and Integrative Health (NCCIH)CompletedAcute Respiratory InfectionUnited States
-
NeuroActiva, Inc.UnknownSevere Acute Respiratory Syndrome | Covid19 | Corona Virus Infection | Severe Acute Respiratory Syndrome (SARS) Pneumonia | Neurodegeneration | Neuroinflammatory Response | Severe Acute Respiratory Infection | Severe Acute Respiratory Syndrome of Upper Respiratory TractUnited States
-
NeuroActiva, Inc.Biomed Industries, Inc.RecruitingCoronavirus Infection | Severe Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory InfectionUnited States
-
Altesa Biosciences, Inc.Virtus Respiratory ResearchRecruitingRCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory InfectionInfections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | Enterovirus Infections | Copd | Pulmonary Disease | Respiratory Disease | Respiratory Complication | Upper Respiratory Tract Infections | Respiratory Viral Infection | ... and other conditionsUnited Kingdom
Clinical Trials on Naso pharyngeal swab
-
French National Agency for Research on AIDS and...CompletedHIV Infections | InfluenzaFrance
-
Centre Hospitalier Universitaire VaudoisCompletedLower Resp Tract InfectionSwitzerland
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Assistance Publique Hopitaux De MarseilleUnknownMeningo-encephalitis | Community-based MeningitisFrance
-
Wissenschaftliches Institut Bethanien e.VCompleted
-
University Children's Hospital, ZurichCompletedDiagnosis | Childhood Pneumonia | Mycoplasma Pneumonia | Antibody-secreting Cells | Enzyme-linked Immunospot (ELISpot)
-
Medical College of WisconsinRecruiting
-
Renmin Hospital of Wuhan UniversityUnknown